The novel pleuromutilin derivative 22–((4-((4-nitrophenyl)acetamido)phenyl)thio)deoxy pleuromutilin possesses robust anti-mycoplasma activity both in vitro and in vivo
This study proved that compound 16C has a strong antimicrobial effect against <i>M. pneumoniae</i>, can be rapidly absorbed and has therapeutic efficacy that provides a basis for developing new anti-mycoplasma drugs.
Authors
- Yaxi Li (ORCID: https://orcid.org/0000-0002-9258-0705)
- Xirui Xia
- Wenxiang Wang (ORCID: https://orcid.org/0009-0002-9542-7746)
- Yue Zhao (ORCID: https://orcid.org/0000-0003-4046-9842)
- Huanzhong Ding (ORCID: https://orcid.org/0000-0002-0123-1228)
- Xuan Ji (ORCID: https://orcid.org/0009-0000-9132-7401)
- Yubo Wang (ORCID: https://orcid.org/0009-0004-7125-9762)
Institutions
- South China Agricultural University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-12-20
- DOI
- https://doi.org/10.3389/fphar.2024.1491223
- Primary Topic
- Veterinary medicine and infectious diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Guangdong Provincial Pearl River Talents Program
- National Key Research and Development Program of China